Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
December 30, 2023 11:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
Eagle Pharmaceuticals Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
December 13, 2023 12:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox notifies investors of Class Action filed against Eagle Pharmaceuticals.
EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
November 30, 2023 16:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
November 29, 2023 14:50 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX).